Home  /   Products  /   Antibacterial  /   Doxycycline (Unidox Solutab) dispersible 100 mg – [10 tablets]

Doxycycline (Unidox Solutab) dispersible 100 mg – [10 tablets]

$12.42

Tetracycline antibiotic

SKU: 63487 Category:

Description

Doxycycline Tablets Unidox Solutab

Pharmacodynamics

Doxycycline (Unidox Solutab) dispersible tablets belong to the broad-spectrum antibiotic tetracycline group. It acts as a bacteriostatic agent, inhibiting protein synthesis in microbial cells by interacting with the 30S ribosome subunit. It effectively targets a wide range of microorganisms, both Gram-positive and Gram-negative, including Streptococcus spp., Treponema spp., Staphylococcus spp., Klebsiella spp, Enterobacter spp. (including E. aerugenes), Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, Listeria monocytogenes, Rickettsia spp., Typhus exanthematicus, Escherichia coli, Shigella spp, Campylobacter fetus, Vibrio cholerae, Yersinia spp. (including Yersinia pestis), Brucella spp., Francisella tularensis, Bacillus anthracis, Bartonella bacilliformis, Pasteurella multocida, Borrelia recurrentis, Clostridium spp. (except Clostridium difficile), Actinomyces spp, Fusobacterium fusiforme, Calymmatobacterium granulomatosis, Propionibacterium acnes, and certain protozoa (Entamoeba spp., Plasmodium falciparum).

It’s worth noting that Doxycycline has no effect on Acinetobacter spp., Proteus spp., Pseudomonas spp., Serratia spp., Providencia spp., or Enterococcus spp. Also, consider the possibility of acquired resistance to doxycycline among certain pathogens, which can often extend to the entire tetracycline group.

Indications

Doxycycline (Unidox Solutab) dispersible tablets are indicated for infectious and inflammatory diseases caused by microorganisms that are sensitive to the drug. This includes respiratory tract infections such as pharyngitis, acute bronchitis, exacerbation of chronic obstructive pulmonary disease, tracheitis, bronchopneumonia, lobar pneumonia, community-acquired pneumonia, lung abscess, and pleural empyema. It is also effective for infections of ENT-organs, urogenital system infections, gastrointestinal and biliary tract infections, skin and soft tissue infections, and eye infectious diseases. It’s even used for postoperative purulent complications and malaria prophylaxis during short-term travels.

Contraindications

  • Hypersensitivity to doxycycline, other tetracyclines, or other drug components
  • Pregnancy
  • Breastfeeding period
  • Childhood under 8 years of age
  • Severe liver and/or kidney dysfunction
  • Porphyria
  • Lactase deficiency, lactose intolerance, glucose-galactose malabsorption

Administration during Pregnancy and Lactation

Doxycycline penetrates the blood-placental barrier, and tetracyclines have adverse effects on the fetus and dental enamel formation. Therefore, tetracyclines are generally avoided during pregnancy except in cases of dangerous infections. Doxycycline should not be used during breastfeeding due to its effect on the fetus. Breastfeeding should be discontinued if tetracyclines need to be administered.

How to Use and Dosages

  • Take the tablet orally.
  • Usually, the treatment duration is 5-10 days.
  • Dissolve the tablet in a small amount of water (at least 50 ml) before use and mix thoroughly until a suspension is obtained. Take the suspension immediately after preparation.
  • Preferably, take it with meals.
  • For adults and children over 8 years old with a body mass over 50 kg: 200 mg in 1 or 2 doses on the first day, then 100 mg daily. Severe infections may require 200 mg daily throughout the treatment.
  • For children aged 8-12 years with a body weight less than 50 kg, the average daily dose is 4 mg/kg on the first day, then 2 mg/kg daily (1-2 times). Severe infections may require 4 mg/kg daily.
  • Dosage adjustments are needed for specific diseases and conditions.
  • Consult a doctor for maximum daily doses and adjustments in cases of renal or hepatic impairment.

[DOXYCYCLINE (UNIDOX SOLUTAB®) AND/OR JOSAMYCIN (WILPRAFEN®) IN TREATMENT OF PATIENTS WITH PROSTATITIS IN REAL CLINICAL PRACTICE. RESULTS OF THE TAURUS OBSERVATIONAL PROGRAM]